NCT04416438 (COVIM) is a clinical trial in Myeloproliferative Neoplasm, sponsored by French Innovative Leukemia Organisation.

Who is sponsoring NCT04416438?

NCT04416438 is sponsored by French Innovative Leukemia Organisation.

What condition does NCT04416438 study?

NCT04416438 studies Myeloproliferative Neoplasm, COVID-19 Infection.

Is NCT04416438 still recruiting?

NCT04416438 is currently completed. Last updated 18 October 2022.

Last reviewed 2022-10-18 · How we verify

NCT04416438: COVIM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

COVID-19 Epidemic and Patients With Myeloproliferative Neoplasias

Completed Last updated 18 October 2022

What this trial tests

trial in Myeloproliferative Neoplasm in 1,793 participants. Completed in 1 September 2022.

Timeline

18 May 2020

Primary endpoint
31 December 2021

1 September 2022

Quick facts

Lead sponsor	French Innovative Leukemia Organisation
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,793
Start date	18 May 2020
Primary completion	31 December 2021
Estimated completion	1 September 2022
Sites	1 location across France

Conditions studied

Myeloproliferative Neoplasm — all drugs for Myeloproliferative Neoplasm →
COVID-19 Infection — all drugs for COVID-19 Infection →

Sponsor

French Innovative Leukemia Organisation — full company profile →

Who can join

18 and older, any sex, with Myeloproliferative Neoplasm or COVID-19 Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The classic myeloproliferative neoplasias (MNP), including polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF) or secondary to PV or ET, are among the most frequent of malignant hemopathies, with overall prevalence estimated at around 10,000 patients followed in France. Due to the median age of patients around 65, the frequency of cardiovascular complications of these thrombogenic diseases and the impact of cytoreductive treatments on immune cells, these patients are considered to be at risk of developing forms severe of COVID-19. This study will assess the impact of MNPs on the risk of developing a severe form of COVID-19, identify new risk factors linked to the disease as well as the impact of treatments for MNPs according to their pharmacological class.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial?
Vivarelli S, Falzone L, Grillo CM, Scandurra G, et al · · 2020 · cited 63× · PMID 32785162 · DOI 10.3390/cancers12082237

Verify or expand the search:

Other recruiting trials for Myeloproliferative Neoplasm

Currently open trials in the same condition.

NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
NCT06468033 — P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk · Phase 3 · recruiting
NCT06815003 — Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Di · Phase 2 · recruiting
NCT05745285 — Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care · NA · recruiting
NCT06553638 — Evaluation of the Prognostic Impact of Decreased Serum beta2 Microglobulin in the First Year of Follow-up of Myeloprolif · active not recruiting

Other French Innovative Leukemia Organisation trials

Trials by the same sponsor.

NCT07007052 — Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Bl · Phase 2 · not yet recruiting
NCT06547866 — Study Evaluating the Efficacy and Tolerance of a Zanubrutinib and BGB-11417 Combination in Patients Previously Treated f · Phase 2 · not yet recruiting
NCT06377579 — OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia · recruiting
NCT06263387 — Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients Ineligible · recruiting
NCT06186648 — Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter S · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04416438 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by French Innovative Leukemia Organisation
Last refreshed: 18 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04416438.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing